Ex vivo activated and expanded donor- or host-type BALB/c CD25+ LSelhi, but not LSello, cell infusion increases donor BM engraftment and TGF-β signaling is not required for engraftment promotion
Donor . | Host . | CD25+ origin . | CD25+ no. . | No. chimeric . | % Donor . |
|---|---|---|---|---|---|
| Exp no. 1 | |||||
| BALB/c | B6 | NA | None | 0/10 | 0 ± 0 |
| BALB/c | B6 | Donor | 10 × 106 LSelhi | 10/10* | 87 ± 6* |
| BALB/c | B6 | Donor | 10 × 106 LSello | 3/10 | 3 ± 4 |
| Exp no. 2 | |||||
| BALB/c | B6 | NA | None | 0/10 | 0 ± 0 |
| BALB/c | B6 | Donor | 6 × 106 LSelhi | 9/9* | 70 ± 10* |
| Exp no. 3 | |||||
| B6 | BALB/c | NA | None | 0/8 | 0 ± 0 |
| B6 | BALB/c | Host | 8.5 × 106 LSelhi | 10/10* | 69 ± 4* |
| B6 | BALB/c | Host | 8.5 × 106 LSello | 0/8 | 0 ± 0 |
| Exp no. 4 | |||||
| BALB/c | B6 β2m-/- DNRII | NA | None | 3/9 | 8 ± 7 |
| BALB/c | B6 β2m-/- DNRII | Donor | 13 × 106 LSelhi | 7/9 | 37 ± 11* |
| Exp no. 5 | |||||
| BALB/c | B6 β2m-/- DNRII | NA | None | 6/8 | 21 ± 10 |
| BALB/c | B6 β2m-/- DNRII | Donor | 10 × 106 LSelhi | 9/9 | 74 ± 3* |
Donor . | Host . | CD25+ origin . | CD25+ no. . | No. chimeric . | % Donor . |
|---|---|---|---|---|---|
| Exp no. 1 | |||||
| BALB/c | B6 | NA | None | 0/10 | 0 ± 0 |
| BALB/c | B6 | Donor | 10 × 106 LSelhi | 10/10* | 87 ± 6* |
| BALB/c | B6 | Donor | 10 × 106 LSello | 3/10 | 3 ± 4 |
| Exp no. 2 | |||||
| BALB/c | B6 | NA | None | 0/10 | 0 ± 0 |
| BALB/c | B6 | Donor | 6 × 106 LSelhi | 9/9* | 70 ± 10* |
| Exp no. 3 | |||||
| B6 | BALB/c | NA | None | 0/8 | 0 ± 0 |
| B6 | BALB/c | Host | 8.5 × 106 LSelhi | 10/10* | 69 ± 4* |
| B6 | BALB/c | Host | 8.5 × 106 LSello | 0/8 | 0 ± 0 |
| Exp no. 4 | |||||
| BALB/c | B6 β2m-/- DNRII | NA | None | 3/9 | 8 ± 7 |
| BALB/c | B6 β2m-/- DNRII | Donor | 13 × 106 LSelhi | 7/9 | 37 ± 11* |
| Exp no. 5 | |||||
| BALB/c | B6 β2m-/- DNRII | NA | None | 6/8 | 21 ± 10 |
| BALB/c | B6 β2m-/- DNRII | Donor | 10 × 106 LSelhi | 9/9 | 74 ± 3* |
Host mice were sublethally irradiated on day-1 and infused with 10 × 106 allogeneic donor BM on day 0. Donor- or host-type BALB/c CD25+ cells were activated and expanded by anti-CD3/CD28-coated beads and IL-2 (100 U/mL) and separated into LSelhi and LSello fractions immediately prior to infusion at the indicated number on day 0 (an additional infusion was given on day 3 in experiment 1 only). PBLs were typed for percentage donor-host at 3 months after BMT. Chimeric is defined as having more than 3% donor PBLs. Percentage donor is defined as average percentage donor cells of all mice in the group ± 1 SEM.
Exp indicates experiment; NA, not applicable.
P < .02 compared to control mice receiving no CD25+ cells